Cargando…

New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries

BACKGROUND: This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia. The aim is to identify current patterns of NPS use and related harms in each country through recordin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurcevič, Eliza, Lines, Rick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703505/
https://www.ncbi.nlm.nih.gov/pubmed/33256747
http://dx.doi.org/10.1186/s12954-020-00448-2
_version_ 1783616652958498816
author Kurcevič, Eliza
Lines, Rick
author_facet Kurcevič, Eliza
Lines, Rick
author_sort Kurcevič, Eliza
collection PubMed
description BACKGROUND: This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia. The aim is to identify current patterns of NPS use and related harms in each country through recording the perspectives and lived experience of people who use drugs and people who provide harm reduction services in order to inform the harm reduction response. METHODOLOGY: The study involved desk-based research and semi-structured interviews/focus groups with 124 people who use drugs and 55 health and harm reduction service providers across the six countries. RESULTS: People who use drugs in all countries were aware of NPS, primarily synthetic cathinones and synthetic cannabinoids. NPS users generally reflected two groups: those with no prior history of illicit drug use (typically younger people) and those who used NPS on an occasional or regular basis due to the lack of availability of their preferred drug (primarily opiates). In many cases, these respondents reported they would not use NPS if traditional opiates were available. Common factors for choosing NPS included cost and accessibility. Respondents in most countries described NPS markets that use the DarkNet and social media for communication, secretive methods of payment and hidden collection points. A recurring theme was the role of punitive drug policies in driving NPS use and related harms. Respondents in all countries agreed that current harm reduction services were important but needed to be enhanced and expanded in the context of NPS. CONCLUSIONS: The study identified patterns and drivers of NPS use, risk behaviours and drug-related harms. It identified gaps in the current harm reduction response, particularly the needs of non-injectors and overdose response, as well as the harmful effects of punitive drug policies. These findings may inform and improve current harm reduction services to meet the needs of people who use NPS.
format Online
Article
Text
id pubmed-7703505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77035052020-12-01 New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries Kurcevič, Eliza Lines, Rick Harm Reduct J Research BACKGROUND: This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia. The aim is to identify current patterns of NPS use and related harms in each country through recording the perspectives and lived experience of people who use drugs and people who provide harm reduction services in order to inform the harm reduction response. METHODOLOGY: The study involved desk-based research and semi-structured interviews/focus groups with 124 people who use drugs and 55 health and harm reduction service providers across the six countries. RESULTS: People who use drugs in all countries were aware of NPS, primarily synthetic cathinones and synthetic cannabinoids. NPS users generally reflected two groups: those with no prior history of illicit drug use (typically younger people) and those who used NPS on an occasional or regular basis due to the lack of availability of their preferred drug (primarily opiates). In many cases, these respondents reported they would not use NPS if traditional opiates were available. Common factors for choosing NPS included cost and accessibility. Respondents in most countries described NPS markets that use the DarkNet and social media for communication, secretive methods of payment and hidden collection points. A recurring theme was the role of punitive drug policies in driving NPS use and related harms. Respondents in all countries agreed that current harm reduction services were important but needed to be enhanced and expanded in the context of NPS. CONCLUSIONS: The study identified patterns and drivers of NPS use, risk behaviours and drug-related harms. It identified gaps in the current harm reduction response, particularly the needs of non-injectors and overdose response, as well as the harmful effects of punitive drug policies. These findings may inform and improve current harm reduction services to meet the needs of people who use NPS. BioMed Central 2020-11-30 /pmc/articles/PMC7703505/ /pubmed/33256747 http://dx.doi.org/10.1186/s12954-020-00448-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kurcevič, Eliza
Lines, Rick
New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
title New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
title_full New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
title_fullStr New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
title_full_unstemmed New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
title_short New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
title_sort new psychoactive substances in eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703505/
https://www.ncbi.nlm.nih.gov/pubmed/33256747
http://dx.doi.org/10.1186/s12954-020-00448-2
work_keys_str_mv AT kurceviceliza newpsychoactivesubstancesineurasiaaqualitativestudyofpeoplewhousedrugsandharmreductionservicesinsixcountries
AT linesrick newpsychoactivesubstancesineurasiaaqualitativestudyofpeoplewhousedrugsandharmreductionservicesinsixcountries